Ketamine Therapy in Indiana: A 2026 Guide

Ketamine therapy has become an increasingly discussed option for Hoosiers living with treatment-resistant depression and related mood disorders. While Indiana is not the largest state, it has a growing set of clinics — concentrated in Indianapolis, Fort Wayne, South Bend, and Bloomington — offering both IV ketamine infusions and the FDA-approved nasal spray Spravato (esketamine). This guide explains what ketamine therapy involves, how Indiana regulates it, what insurance coverage looks like, and how to approach finding a provider.

How Ketamine Therapy Works

Ketamine is an anesthetic medication that, at carefully controlled sub-anesthetic doses, can produce rapid reductions in depressive symptoms in some patients. Unlike most antidepressants that take weeks to show effect, some patients report symptom relief within hours or days of an infusion. The mechanism is not fully understood, but research points to ketamine’s interaction with NMDA glutamate receptors as distinct from the serotonin pathways most antidepressants target.

The FDA approved Spravato (esketamine) in 2019 specifically for treatment-resistant depression (ICD-10: F33.2) — defined clinically as failing to respond to at least two adequate antidepressant trials — and later for major depressive disorder with acute suicidal ideation (ICD-10: F32.9). IV ketamine infusions remain off-label and are billed using general procedural codes such as 99213/99214 for evaluation and management, 90791 for psychiatric evaluation, and J3490 for off-label drug administration.

Ketamine is not appropriate for everyone. Conditions such as uncontrolled high blood pressure, active psychosis, or certain cardiac conditions may preclude treatment. A thorough evaluation by a licensed clinician is always the first step.

Indiana’s Regulatory Framework for Ketamine

Ketamine prescribing and administration in Indiana falls under the oversight of the Medical Licensing Board of Indiana, a division of the Indiana Professional Licensing Agency (IPLA). Physicians (MDs and DOs) licensed by this board may prescribe and administer ketamine within their scope of practice. Advanced practice registered nurses (APRNs) in Indiana must maintain a collaborative practice agreement with a physician for prescribing controlled substances, which includes ketamine.

Indiana requires physicians to maintain complete medical records, follow standard-of-care protocols, and conduct appropriate pre-treatment evaluations. For Spravato specifically, the FDA’s REMS (Risk Evaluation and Mitigation Strategy) program applies regardless of state — meaning Spravato must be administered in a certified healthcare setting with a mandatory two-hour post-dose observation window. Patients cannot take Spravato home.

You can verify a physician’s Indiana license status through the Indiana Professional Licensing Agency’s online license lookup. The NPPES NPI Registry is also a useful tool for confirming a provider’s specialty and practice address.

Indiana has not enacted specific ketamine clinic regulations beyond general medical practice standards, so the quality and protocols of individual clinics can vary considerably. This makes due diligence by patients especially important.

Insurance and the Indiana Payer Landscape

Spravato (esketamine) has a more established insurance pathway than IV ketamine because it is FDA-approved.

Indiana Health Coverage Programs (IHCP) / Healthy Indiana Plan (HIP): Indiana’s Medicaid program, administered through the Indiana Health Coverage Programs (IHCP) — which includes the state’s Healthy Indiana Plan (HIP) — covers Spravato for eligible members who meet clinical criteria. Prior authorization is required, and the treating clinician must document the patient’s diagnosis and prior medication failures. Managed care entities within Indiana Medicaid, including MDwise and CareSource Indiana, each have their own prior authorization workflows. Patients should contact their specific plan to verify current formulary status and requirements.

Anthem Blue Cross Blue Shield of Indiana is one of the largest commercial insurers in the state and participates broadly in Indiana’s employer-sponsored, individual marketplace, and Medicaid markets. Anthem Indiana has a medical policy for Spravato that requires prior authorization and documentation of treatment-resistant depression meeting clinical criteria. Members should confirm their specific plan tier and prior authorization requirements by calling the member services number on their insurance card.

Other significant commercial payers in Indiana include:

UnitedHealthcare of Indiana — covers Spravato subject to prior authorization and step therapy
Cigna Indiana — prior authorization required with clinical criteria documentation
Aetna Indiana — follows Aetna’s national medical policy for Spravato coverage

IV ketamine infusions are rarely covered by any commercial plan and are typically a direct out-of-pocket cost for Indiana patients.

The Mental Health Context in Indiana

Indiana has faced documented challenges with mental health access — rural areas of the state in particular have historically had fewer psychiatrists and mental health providers per capita than urban centers. Ketamine therapy may appeal to patients who have exhausted available traditional treatments, but the geographic concentration of ketamine clinics in urban centers means rural Hoosiers may face significant travel burdens.

Some Indiana providers have adapted by offering telehealth evaluations for the intake and follow-up components of ketamine care. Indiana’s telehealth framework, expanded during the COVID-19 public health emergency, has remained relatively supportive of telehealth for mental health services. However, the actual administration of IV ketamine or Spravato must occur in person at a licensed facility — telehealth cannot substitute for the in-office treatment session.

For Indiana residents in rural areas considering ketamine therapy, it may be worth discussing with your primary care physician or psychiatrist whether the travel involved is feasible and whether Spravato (which has a clearer insurance pathway) might be preferable to IV ketamine given your circumstances.

What an Initial Series Looks Like

For IV ketamine, most Indiana clinics offer an initial series of six infusions spread over two to three weeks. Each infusion typically lasts 40 to 60 minutes, and patients must arrange a driver for the day of each session. During the infusion, patients often experience dissociative effects — altered perception, a dreamlike state — that resolve quickly afterward.

For Spravato, the FDA-approved dosing schedule starts with twice-weekly sessions for the first four weeks, weekly sessions for weeks five through eight, and weekly or biweekly maintenance thereafter. Each session includes the supervised self-administration and the mandatory two-hour observation period.

Neither format replaces ongoing mental health care. Most clinicians recommend continuing or initiating psychotherapy alongside ketamine treatment, as evidence suggests the combination produces more durable outcomes than ketamine alone.

Find an Indiana ketamine provider through our directory.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.